Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

8.3%

1 terminated/withdrawn out of 12 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

92%

11 trials in Phase 3/4

Results Transparency

25%

2 of 8 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 3

9(81.8%)

Phase 4

2(18.2%)

11Total

Phase 3(9)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials

NCT00477685Completed

Ologen (OculusGen)-Phacotrabeculectomy Historical Control Study in India

Role: lead

NCT00448929Phase 3Completed

Ologen (OculusGen)-Glaucoma Case Control Trial in India

Role: lead

NCT00524758Phase 3Completed

Oculusgen (Ologen) Glaucoma MMC Control in Estonia

Role: lead

NCT00538590Phase 4Completed

Ologen Collagen Matrix Safety and Effective Comparison With Mitomycin-C(MMC) in Glaucoma Surgery

Role: lead

NCT00478790Phase 3Unknown

Ologen(Oculusgen)-Glaucoma and Pterygium Historical Control Study in China Shanghai Sixth People's Hospital

Role: lead

NCT00449098Phase 4Unknown

Ologen (OculusGen)-Glaucoma MMC Control Trial in India

Role: lead

NCT00472810Phase 3Completed

Ologen (OculusGen)-Glaucoma MMC Control in Pakistan

Role: lead

NCT00687791Phase 3Unknown

Oculusgen (Ologen) Collagen Matrix Implant for Phaco-Trabeculectomy in Primary Glaucoma: A Case-Control Study

Role: lead

NCT00320957Phase 3Completed

Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in China Zhong-Shan Hospital

Role: lead

NCT00320762Phase 3Completed

Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in China Beijing Hospital

Role: lead

NCT00321035Phase 3Completed

Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in Beijing Remin Hospital

Role: lead

NCT00406822Phase 3Terminated

OculusGen-Glaucoma Historical Control Study in Taiwan

Role: lead

All 12 trials loaded